select a format

Single User License
USD 125 INR 8115
Site License
USD 250 INR 16230
Corporate User License
USD 375 INR 24345

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


Biogen Inc (BIIB)-Financial and Strategic SWOT Analysis Review

Biogen Inc (BIIB)-Financial and Strategic SWOT Analysis Review


  • Products Id :- GDPH1307FSA
  • |
  • Pages: 64
  • |
  • March 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Biogen Inc (BIIB)-Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description-A detailed description of the company's operations and business divisions.

Corporate strategy-Analyst's summarization of the company's business strategy.

SWOT Analysis-A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history-Progression of key events associated with the company.

Major products and services-A list of major products, services and brands of the company.

Key competitors-A list of key competitors to the company.

Key employees-A list of the key executives of the company.

Executive biographies-A brief summary of the executives' employment history.

Key operational heads-A list of personnel heading key departments/functions.

Important locations and subsidiaries-A list and contact details of key locations and subsidiaries of the company.

Key manufacturing facilities-A list of key manufacturing facilities of the company.

Detailed financial ratios for the past five years-The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods-The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbryta (daclizumab), Fampyra (prolonged-release fampridine tablets) and Plegridy (peginterferon beta-1a) for the treatment of multiple sclerosis (MS); Spinraza (nusinersen) for spinal muscular atrophy (SMA); and Fumaderm (fumaric acid esters) for plaque psoriasis. The company also offers biosimilars through its joint venture, Samsung Bioepis. It has several products candidates targeting various indications such as MS, Parkinson's disease, Alzheimer's disease and Non-Hodgkin's lymphoma, among others. The company sells its products through direct sales forces, marketing groups and distributors in the Americas, Europe, Asia and Other territories. Biogen is headquartered in Cambridge, Massachusetts, the US.

Biogen Inc Key Recent Developments

Feb 01, 2017: Biogen Completes Separation of Global Hemophilia Business, Bioverativ

Jan 26, 2017: Biogen Reports 2016 Revenues of $11.4 Billion

Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock

Dec 22, 2016: Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement

Dec 19, 2016: Biogen Names Michel Vounatsos Chief Executive Officer

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Section 1-About the Company 6

Biogen Inc-Key Facts 6

Biogen Inc-Key Employees 7

Biogen Inc-Key Employee Biographies 8

Biogen Inc-Major Products and Services 9

Biogen Inc-Pharmaceutical Pipeline Products Data 11

Biogen Inc, Pipeline Products by Therapy Area 11

Biogen Inc, Pipeline Products by Development Phase 12

Biogen Inc-History 13

Biogen Inc-Company Statement 23

Biogen Inc-Locations And Subsidiaries 27

Head Office 27

Other Locations & Subsidiaries 27

Joint Venture 31

Section 2-Company Analysis 32

Biogen Inc-Business Description 32

Biogen Inc-Corporate Strategy 34

Biogen Inc-SWOT Analysis 35

SWOT Analysis-Overview 35

Biogen Inc-Strengths 35

Biogen Inc-Weaknesses 36

Biogen Inc-Opportunities 37

Biogen Inc-Threats 38

Biogen Inc-Key Competitors 39

Section 3-Company Financial Ratios 40

Financial Ratios-Capital Market Ratios 40

Financial Ratios-Annual Ratios 41

Performance Chart 43

Financial Performance 43

Financial Ratios-Ratio Charts 44

Section 4-Company's Lifesciences Financial Deals and Alliances 45

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 45

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 46

Biogen Inc, Recent Deals Summary 47

Section 5-Company's Recent Developments 48

Feb 01, 2017: Biogen Completes Separation of Global Hemophilia Business, Bioverativ 48

Jan 26, 2017: Biogen Reports 2016 Revenues of $11.4 Billion 49

Jan 12, 2017: Biogen Spin-off Bioverativ Commences When-Issued Trading of Common Stock 51

Dec 22, 2016: Biogen Announces Effectiveness of Bioverativ Form 10 Registration Statement 52

Dec 19, 2016: Biogen Names Michel Vounatsos Chief Executive Officer 53

Nov 30, 2016: Sangamo's Genome Editing Program for Hemoglobinopathies to Transfer to Biogen's Spin-Off Bioverativ 54

Nov 15, 2016: Biogen announces management changes 55

Oct 26, 2016: Biogen Reports Record Third Quarter 2016 Revenues of $3.0 Billion 56

Sep 21, 2016: Bio-pharma and CROs Convene at Bioclinica's 2016 Global eHealth Conference 58

Sep 13, 2016: IXICO presents Assessa PML digital healthcare platform supported by Biogen at International Multiple Sclerosis Congress 59

Section 6-Appendix 60

Methodology 60

Ratio Definitions 60

About GlobalData 64

Contact Us 64

Disclaimer 64

List of Figures

Biogen Inc, Pipeline Products by Therapy Area 11

Biogen Inc, Pipeline Products by Development Phase 12

Biogen Inc, Performance Chart (2012-2016) 43

Biogen Inc, Ratio Charts 44

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 45

Biogen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 46

List of Tables

Biogen Inc, Key Facts 6

Biogen Inc, Key Employees 7

Biogen Inc, Key Employee Biographies 8

Biogen Inc, Major Products and Services 9

Biogen Inc, Number of Pipeline Products by Therapy Area 11

Biogen Inc, Number of Pipeline Products by Development Stage 12

Biogen Inc, History 13

Biogen Inc, Other Locations 27

Biogen Inc, Subsidiaries 27

Biogen Inc, Joint Venture 31

Biogen Inc, Key Competitors 39

Biogen Inc, Ratios based on current share price 40

Biogen Inc, Annual Ratios 41

Biogen Inc (Cont...1), Annual Ratios 42

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 45

Biogen Inc, Pharmaceuticals & Healthcare, Deals By Type, 2011 to YTD 2017 46

Biogen Inc, Recent Deals Summary 47

Currency Codes 60

Capital Market Ratios 60

Equity Ratios 61

Profitability Ratios 61

Cost Ratios 62

Liquidity Ratios 62

Leverage Ratios 62

Efficiency Ratios 63

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Teva Pharmaceutical Industries Ltd, Sanofi, Pfizer Inc, Novartis AG, Merck & Co Inc, Bayer HealthCare Pharmaceuticals, AbbVie Inc

Biogen Inc, SWOT analysis, SWOT, Strengths, Weaknesses, Opportunities, Threats, Corporate Strategy, Key Ratios, Share Data, Performance, Financial Performance, Overview, Business Description, Major Product, Brands, History,Key Employees, Key Operational Heads, Strategy, Key Competitors, Company Statement, Capital Market Ratios, Financial Ratios, Annual Ratios, Interim Ratios, Ratio Charts


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com